HF
YMAB

HRT Financial’s Y-mAbs Therapeutics YMAB Stock Holding History

HRT Financial’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-14,260
Closed -$187K – 3377
2024
Q3 		$187K Buy
+14,260
New +$181K ﹤0.01% 1990
2024
Q2 		– Sell
-16,216
Closed -$263K – 3241
2024
Q1 		$263K Buy
+16,216
New +$219K ﹤0.01% 1628
2023
Q1 		– Sell
-66,265
Closed -$323K – 3301
2022
Q4 		$323K Buy
+66,265
New +$481K ﹤0.01% 1680
2022
Q3 		– Sell
-31,678
Closed -$479K – 3609
2022
Q2 		$479K Buy
+31,678
New +$370K 0.01% 1680
2021
Q1 		– Sell
-7,467
Closed -$369K – 3230
2020
Q4 		$369K Buy
+7,467
New +$345K 0.01% 1178

Other funds holding YMAB

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HRT Financial's YMAB Position: Q4 2024 in Review

HRT Financial sold out of Y-mAbs Therapeutics (YMAB) in Q4 2024, closing a stake of 14,260 shares — an estimated $187K sold.

HRT Financial first reported a position in YMAB in Q4 2020 and held it in 5 quarters. The position peaked at $479K in Q2 2022. 112 funds tracked by Wall St. Rank hold YMAB as of Q4 2024.

  • HRT Financial reported no remaining Y-mAbs Therapeutics position as of Q4 2024 after selling out during the quarter.
  • HRT Financial sold 14,260 Y-mAbs Therapeutics shares in Q4 2024, an estimated $187K.
  • HRT Financial first reported a position in Y-mAbs Therapeutics in Q4 2020 and held it in 5 quarters.
  • HRT Financial's Y-mAbs Therapeutics position peaked at $479K in Q2 2022.
  • 112 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q4 2024.

Based on HRT Financial's 13F filing for Q4 2024, filed 14 Feb 2025.